FDA and Avastin: More Questions Than Answers

Article

According to ONCOLOGY contributor, Debu Tripathy, MD, FDA's process for the final approval of Avastin for advanced breast cancer raises many questions about the standards on drug approval in this changing era of targeted therapy and personalized medicine.

According to ONCOLOGY contributor, Debu Tripathy, MD, FDA's process for the final approval of Avastin for advanced breast cancer raises many questions about the standards on drug approval in this changing era of targeted therapy and personalized medicine.

Read Dr. Tripathy's interesting and provocative take on the issue in this posting.

According to a commentary by Lee Schwartzberg, MD

Although these results [E2100, AVADO, and RIBBON-1] confirmed and extended the value of bevacizumab for many attendees at ASCO, the FDA’s Oncology Drug Advisory Committee (ODAC), which met in July 2010, drew very different conclusions from the same data. ODAC voted 12 to 1 to veto the indication of bevacizumab in the first-line treatment of MBC based on the “unfavorable risk/benefit ratio.” The lack of an overall survival difference was particularly influential to this decision.

Many breast cancer oncologists would disagree vehemently with ODAC, instead endorsing the concept that a 2.5-month median improvement in PFS was, in fact, a meaningful endpoint. Moreover, clinicians are adept at handling the modest increase in toxicity engendered by the addition of bevacizumab, and they believe that, clinically, there is little to no decrement in quality of life from adding this agent.

It remains to be seen whether the FDA will withdraw the approval of bevacizumab for MBC. If it does, there could be profound changes in the way other drugs are evaluated for this disease. With regard to other antiangiogenic agents in MBC, the future is uncertain.

Look for upcoming coverage as this important issue unfolds…

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content